Pan in Medical Technology

Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C

...evidence of any mitochondrial or other cellular toxicities that may be associated with some nucleoside analogs. Like RG7128, PSI-7851 has demonstrated pan genotype activity in vitro . About Pharmasset Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing,...

Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th

... Additional Clinical Studies Also Highlighted at pan Pacific Conference Randomized... "PIX 301 EXTEND trial") is being presented at the pan Pacific Lymphoma conference by Dr. Richard Van der...gressive first-line therapy with CHOP-R. The pan Pacific Lymphoma Conference poster is available at...

Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting

...t restore the natural potential for cancer cells to undergo cell death (apoptosis). Ascenta's lead agent, AT-101, is an orally-active small molecule pan Bcl-2 inhibitor (Bcl-2, Bcl-xL, and Mcl-1) currently in Phase 2 clinical trials in castrate resistant prostate cancer. The Company's preclinical pipe...

USAID Provides $5M in Emergency Support as Swine Flu Spreads

...ncy for International Development (USAID) announced today that it is providing an additional $5 million to the World Health Organization (WHO) and the pan American Health Organization (PAHO) in emergency support for efforts to detect and contain the disease in Mexico. "Since 2005, USAID has commit...

Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier

... orally active, novel, small molecule inhibitor of pan HDAC enzymes, that is currently in Phase I/II clin...ing and commercializing its innovative anti-cancer pan HDAC inhibitor agents. "This alliance with Se...tially commercialize our unique and differentiated pan HDAC inhibitor product outside of the United State...

Semafore's SF1126 Exhibits Antitumor and Antiangiogenic Activity

...mor and antiangiogenic activity. The paper, entitled "A Vascular Targeted pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Ant...ancer model. "The data further support our belief that SF1126 is a viable pan PI3K inhibitor as we continue Phase I clinical trials," said Ed Jacobs, Sem...

Ascenta Therapeutics Highlights Multiple Data Presentations at Upcoming AACR Annual Meeting

... growth by combined treatment with MD, PhD the pan Bcl-2 inhibitor AT-101 Ascenta and docetaxel in hu...------------------------------- -------------- A novel pan inhibitor of Bcl-2 and Xiongwen Mcl-1, apogossypolone...

CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings

...go, IL, June 2-5, 2007. A poster presentation will also be made at the 2007 pan Pacific Lymphoma Conference, which is being hosted on the Island of Maui, H... session on Sunday, June 3rd\from 8:00 a.m. - 12:00 p.m. 2007 pan Pacific Lymphoma Conference -- A poster presentation entitled, "A Pha...

Global Rabies Treatment May be Possible with NanoViricides Drugs

...es against rabies that were presented along with the successful BSL3 in vitro studies against a Clade 2 H5N1 virus at the 23rd Annual Symposium of the pan American Society for Clinical Virology in Tampa, FL, on Wednesday, May 2. (Pan American Society for Clinical Virology (PASCV): Clinical Virology Sympo...

Geron's Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial

...s with chronic lymphocytic leukemia (CLL), according to data presented today by Alan Colowick, M.D., M.P.H., the company's president, oncology, at the pan Pacific Lymphoma Conference in Maui, Hawaii. Favorable Pharmacokinetics; Pharmacodynamics Consistent with Expectations A pharmacokinetic analysis o...

CuraGen Presents Update on Clinical Development Program for Belinostat

... cancers. A conference call is being hosted at 8:30 a.m. Eastern time on June 12, 2007, to review these results including data presented at the 2007 pan Pacific Lymphoma Conference being held this week in Maui, HI, and data presented at the 2007 American Society of Clinical Oncology (ASCO) meeting. "...

Publication Confirms that EpCAM, the Target for Two of Micromet's Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers

...ollins AT, Berry PA, Hyde C et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-51 6 pan CX, Zhu W, Cheng L. Implications of cancer stem cells in the treatment of cancer. Future Oncol 2006; 2: 723-31 7 Baeuerle PA, Gires 0. E...